What are the major differences in biomarker test adoption in European countries? An analysis of PD–L1 testing in Italy and Germany

(February 23, 2017)

Sponsored by

Webinar Description:
Key to the success of precision medicine is implementation of biomarker testing. The success of therapies based on immuno-oncology, with over six indications in recent years (predominantly lung cancer), has highlighted the need for PD-L1 biomarker testing and the challenges it raises for implementation. In this webinar, we will discuss the adoption of PD-L1 testing in Europe using Germany and Italy as examples, to understand how different environments can generate different adoption rates, and look at how the process could be optimized.

Learning Objectives:

• High level overview of the pathology testing landscape in Germany and Italy
• Overview of current PD-L1 testing landscape in Germany and Italy
• Understand the market differences
• Gap analysis and possible scenarios

Speakers:

Luiz Gustavo Guedes Corrêa, Ph.D.
Diaceutics

Jordan Clark, Ph.D.
Diaceutics

(February 23, 2017)